AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
KOSPI rises on Samsung Electronics while KOSDAQ falls with Alteogen decline KOSPI closes higher thanks to strong Samsung ...
The Chosun Ilbo on MSN6d
S. Korea's biotech sector kicks off 2025 with multi-billion-dollar dealsS. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...
FDA finds benzene contamination, Tronox to close a pigment plant, Sofinnova launches a European biotech fund, and more ...
Zacks Investment Research on MSN4d
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A DealsThis week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...
AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback